Relutrigine

Name: Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies: Economic impact of diagnostic testing
Published: 2026-09-14T15:39:06-04:00

SCN2A- and SCN8A-related developmental and epileptic encephalopathies

Manufacturer: Praxis Precision Medicines
Regulatory submission: NDA submitted in early 2026
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description Burden of SCN2A- and SCN8A-related developmental and epileptic encephalopathies

Economic impact of diagnostic testing

1 evidence topic · 1 source

UK neonatal epilepsy: earlier gene-panel testing, not relutrigine-specific

“In neonates, the cost of investigations could be reduced from £9362 to £2838 by performing gene panel earlier” (opens the source at this quote in a new tab)